Association of placental transfer of anti-Haemophilus influenzae type b polysaccharide antibodies with their V regions

Park, M.K.; Englund, Janet A.; Glezen, W. Paul; Siber, George R.; Nahm, Moon H.

doi:10.1016/s0264-410x(96)00029-1

Cited by 6 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody placental crossing is moreover subject to the vaccination time through pregnancy [ 116 ]. The detection of factors affecting antibody placental crossing may be fundamental to choosing plans for future maternal immunization [ 118 ].…”

Section: Future Perspectivesmentioning

confidence: 99%

Hib Vaccines: Past, Present, and Future Perspectives

Zarei

Almehdar

Redwan

2016

Journal of Immunology Research

View full text Add to dashboard Cite

Haemophilus influenzae type b (Hib) causes many severe diseases, including epiglottitis, pneumonia, sepsis, and meningitis. In developed countries, the annual incidence of meningitis caused by bacteria is approximately 5–10 cases per population of 100,000. The Hib conjugate vaccine is considered protective and safe. Adjuvants, molecules that can enhance and/or regulate the fundamental immunogenicity of an antigen, comprise a wide range of diverse compounds. While earlier developments of adjuvants created effective products, there is still a need to create new generations, rationally designed based on recent discoveries in immunology, mainly in innate immunity. Many factors may play a role in the immunogenicity of Hib conjugate vaccines, such as the polysaccharides and proteins carrier used in vaccine construction, as well as the method of conjugation. A Hib conjugate vaccine has been constructed via chemical synthesis of a Hib saccharide antigen. Two models of carbohydrate-protein conjugate have been established, the single ended model (terminal amination-single method) and cross-linked lattice matrix (dual amination method). Increased knowledge in the fields of immunology, molecular biology, glycobiology, glycoimmunology, and the biology of infectious microorganisms has led to a dramatic increase in vaccine efficacy.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

Hib Vaccines: Past, Present, and Future Perspectives

Zarei

Almehdar

Redwan

2016

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

Maternal immunization efforts of the National Institutes of Health

Rubin¹,

Koso‐Thomas

Isaacs³

et al. 2015

Vaccine

View full text Add to dashboard Cite

Over the last 35 years, efforts at the National Institutes of Health (NIH) to protect mothers and their infants against infectious diseases have involved a bench-to-bedside approach. Basic and translational research that provided a foundation for clinical trials of vaccines in pregnancy include natural history and vaccine antigen identification studies. Development of laboratory assays and reagents have been funded by NIAID; these are critical for the advancement of vaccine candidates through the preclinical and clinical steps along the maternal immunization research pathway to support vaccine efficacy. Animal models of maternal immunization have been developed to evaluate efficacy of vaccine candidates. Clinical studies required development of maternal immunization protocols to address specific pregnancy related issues, for enrollment and safety assessment of mothers and their infants. NIH has organized and participated in meetings, workshops and other collaborative efforts with partners have advanced maternal immunization efforts. Partners have included many institutes and offices at NIH as well as other Department of Health and Human Services agencies and offices (Food and Drug Administration, Centers for Disease Control and Prevention, National Vaccine Program Office), World Health Organization, academic investigators, Biotech and pharmaceutical companies, and nonprofit organizations such as the Bill and Melinda Gates Foundation. These research and development partnership are essential for advancing maternal immunization. Continued efforts are needed to promote maternal immunization to protect pregnant women and their infants against vaccine-preventable infectious disease, especially in resource-limited settings where the burden of infections is high.

show abstract

Maternal vaccines

Glezen¹

2001

Primary Care: Clinics in Office Practice

View full text Add to dashboard Cite

Acute lower respiratory illness (LRI) is the leading cause of disease worldwide as measured by disability-adjusted life years. New strategies are necessary to decrease the disease burden that is largely borne by infants. Respiratory syncytial virus is the most important cause of LRI in infants. Lower respiratory illness can be prevented by endowing infants with high levels of neutralizing antibodies from mothers whose antibodies are boosted during pregnancy with a potent subunit vaccine. Another important cause of infant mortality is group B streptococcus sepsis in the neonatal period; maternal immunization with a group B conjugate vaccine could prevent this devastating infection.

show abstract

Association of placental transfer of anti-Haemophilus influenzae type b polysaccharide antibodies with their V regions

Cited by 6 publications

References 14 publications

Hib Vaccines: Past, Present, and Future Perspectives

Hib Vaccines: Past, Present, and Future Perspectives

Maternal immunization efforts of the National Institutes of Health

Maternal vaccines

Contact Info

Product

Resources

About